Cefpodoxime
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Cefpodoxime: From Bacterial Infections to Osteoarthritis Susceptibility
One-Sentence Summary
Cefpodoxime is an oral third-generation cephalosporin antibiotic, used to treat bacterial infections. The TxGNN model predicts it may be relevant to osteoarthritis susceptibility, but 0 clinical trials and 0 publications currently support this direction. This is a model-only prediction and should be treated as a hypothesis, not an actionable repurposing candidate.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA registration data (antibacterial cephalosporin) |
| Predicted New Indication | Osteoarthritis susceptibility |
| TxGNN Prediction Score | 99.35% |
| Evidence Level | L5 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the record. Cefpodoxime is a third-generation cephalosporin. As a class, these drugs inhibit bacterial cell wall synthesis by binding penicillin-binding proteins. Its efficacy is in bacterial infections.
No established mechanistic link to osteoarthritis susceptibility was identified. No human target relevant to genetic susceptibility to osteoarthritis is documented for cefpodoxime. The high TxGNN score (99.35%) comes from the knowledge-graph model alone, with no trial or publication behind it.
The other top-ranked predictions show the same pattern. All have scores of 98.6–99.2% and no supporting trials or literature:
- Osteoarthritis (99.25%) and rheumatoid arthritis (99.24%): no known analgesic, disease-modifying or immunomodulatory action of cefpodoxime.
- Hemoglobinopathy (98.84%): an inherited globin disorder. Any use would be indirect, such as infection prophylaxis, which is not a repurposing indication.
- Rare skeletal and developmental dysplasias (brachyolmia, acromesomelic dysplasia Hunter-Thompson type, pseudoachondroplasia, brachyolmia-amelogenesis imperfecta syndrome, colobomatous microphthalmia-rhizomelic dysplasia syndrome) and myosclerosis: genetic conditions with no plausible antibacterial mechanism. These are likely knowledge-graph artifacts.
Clinical Trial Evidence
Currently no related clinical trials registered (ClinicalTrials.gov, ICTRP, SANCTR or PACTR records were not identified in the evidence pack).
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 54/20.1.1/0469 | Cefpodoxime 100 Mg Ascend | Tablet (oral) | Not stated in registration record |
| Reg. No. 43/20.1.1/0245 | Orchid Cefpodoxime 40 Mg/ 5 Ml | Suspension | Not stated in registration record |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
No drug-interaction records were found for this drug in the evidence pack.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on model output alone (evidence level L5). There are no clinical trials or publications, and no plausible mechanism links an antibacterial cephalosporin to osteoarthritis susceptibility or the other predicted conditions. Using an antibiotic outside its infection indications also carries antimicrobial-resistance concerns.
To proceed, the following is needed:
- SAHPRA Professional Information (package insert) for warnings and contraindications, so that safety screening can begin
- Mechanism of action data (for example from DrugBank) to test whether any human-target link exists
- Any preclinical or observational evidence connecting cefpodoxime to osteoarthritis or rheumatoid arthritis. Without it, the candidate should not advance beyond model prediction.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.